These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 3282793)
1. Interleukin-1 and biocompatibility in haemodialysis. Shaldon S; Dinarello C; Elie M; Koch KM Contrib Nephrol; 1988; 62():128-31. PubMed ID: 3282793 [No Abstract] [Full Text] [Related]
2. Quantitation of membrane biocompatibility. Colton CK Contrib Nephrol; 1987; 59():110-25. PubMed ID: 3502085 [No Abstract] [Full Text] [Related]
3. Complement activation and induction of interleukin-1 production during hemodialysis. Haeffner-Cavaillon N; Fischer E; Bacle F; Carreno MP; Maillet F; Cavaillon JM; Kazatchkine MD Contrib Nephrol; 1988; 62():86-98. PubMed ID: 3282802 [No Abstract] [Full Text] [Related]
4. Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA Nephrol Dial Transplant; 1995; 10 Suppl 3():25-8. PubMed ID: 7494610 [TBL] [Abstract][Full Text] [Related]
5. Complement activation as index of haemodialysis membrane biocompatibility: the choice of methods and assays. Cheung AK Nephrol Dial Transplant; 1994; 9 Suppl 2():96-103. PubMed ID: 8065623 [No Abstract] [Full Text] [Related]
6. The interleukin hypothesis: a quantitative assessment. Colton CK Kidney Int Suppl; 1988 Mar; 24():S27-9. PubMed ID: 3258938 [No Abstract] [Full Text] [Related]
7. Haemodialysis membranes modulate chronically the production of TNF alpha, IL1 beta and IL6. Mege JL; Olmer M; Purgus R; Bertocchio P; Farnarier C; Kaplanski S; Capo C; Bongrand P Nephrol Dial Transplant; 1991; 6(11):868-75. PubMed ID: 1775252 [TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of artificial organs: an overview. Henderson LW; Chenoweth D Blood Purif; 1987; 5(2-3):100-11. PubMed ID: 3304344 [TBL] [Abstract][Full Text] [Related]
9. Which level of cytokine production is critical in haemodialysis? Cappelli G; DiFelice A; Perrone S; Ballestri M; Bonucchi D; Savazzi AM; Ciuffreda A; Lusvarghi E Nephrol Dial Transplant; 1998; 13 Suppl 7():55-60. PubMed ID: 9870439 [TBL] [Abstract][Full Text] [Related]
10. Haemodialysis-membrane-induced phagocyte oxidative metabolism activation and interleukin-1 production. Descamps-Latscha B; Herbelin A; Nguyen AT; Uzan M; Zingraff J Life Support Syst; 1986; 4(4):349-53. PubMed ID: 3494170 [No Abstract] [Full Text] [Related]
11. Mechanisms and consequences of complement activation during hemodialysis. Kazatchkine MD; Haeffner-Cavaillon N Adv Exp Med Biol; 1989; 260():19-26. PubMed ID: 2624243 [No Abstract] [Full Text] [Related]
17. Human interleukin-1 production during hemodialysis. Bingel M; Lonnemann G; Shaldon S; Koch KM; Dinarello CA Nephron; 1986; 43(3):161-3. PubMed ID: 3487741 [No Abstract] [Full Text] [Related]
18. Clinical importance of biocompatibility and its effect on haemodialysis treatment. Opatrný K Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v41-4. PubMed ID: 12817068 [No Abstract] [Full Text] [Related]
19. Induction of interleukin-1 during hemodialysis. Haeffner-Cavaillon N; Jahns G; Poignet JL; Kazatchkine MD Kidney Int Suppl; 1993 Jan; 39():S139-43. PubMed ID: 8468916 [No Abstract] [Full Text] [Related]
20. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Girndt M; Heisel O; Köhler H Nephrol Dial Transplant; 1999 Mar; 14(3):676-82. PubMed ID: 10193818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]